Briefing
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
NCT07823322 (NEXERA-204) is an Incyte-sponsored, not-yet-recruiting, single-arm phase 2 study of INCA33890 in about 40 adults with Signatera-positive, microsatellite-stable stage II/III colorectal cancer after curative resection and chemotherapy, with ctDNA clearance at 3 months as the primary endpoint; Natera announced a clinical collaboration on this study on November 10, 2026.
- Design: Phase 2 · Not yet recruiting